Male hypogonadism (or low testosterone) is a condition characterized by testosterone deficiency and persistent clinical symptoms. Its incidence varies from 2%–5% of males aged 40 years and above and sufferers can experience adverse physical and psychological effects, with a subsequent reduction in quality of life. Symptoms comprise of reduced libido, erectile dysfunction, exhaustion, decrease in muscle mass, mood depression, osteoporosis, and deterioration of secondary sexual physiognomies.
Testavan is a novel testosterone replacement therapy considered to reestablish testosterone levels to a standard range (300–1050 ng/dL) in adult males with hypogonadism. Ferring Pharmaceuticals declared the launch of Testavan 20 mg/g transdermal gel for the treatment of adult male population suffering from hypogonadism in the UK in September 2018.
In phase III trials, men treated with Testavan achieved normalized testosterone levels by month three, with improvements in quality of life and fatigue scores over three months, and initial and continual increase in erectile function score at 1 and 3 months. Assessment procedures included testosterone responder rate, defined as the percentage of subjects accomplishing normalized levels of testosterone (300-1050 ng/dL); the Multidimensional Assessment of Fatigue (MAF); general well-being assessment (Short Form 12 Health Survey, SF-12); International Index of Erectile Function (IIEF).
Testavan provides male hypogonadism sufferers with a new treatment option to help restore testosterone levels. Testavan is a contemporary gel with a patented design, based on Ferring’s Advanced Skin Technology (F.A.S.T.), which is designed to provide optimal absorption and bioavailability. Restoring testosterone levels to within the normal range can result in improvements over time in muscle mass, mood, sexual desire, libido and sexual function including sexual performance and number of spontaneous erections.
– Victor Mukherjee,